Ensysce Biosciences, Inc. (ENSC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Federal grants | 1,371,438 | 1,319,772 | 3,418,853 | 181,797 |
| Research and development | 1,923,430 | 1,885,528 | 1,690,674 | 947,229 |
| General and administrative | 1,198,523 | 1,401,756 | 1,083,433 | 1,190,010 |
| Total operating expenses | 3,121,953 | 3,287,284 | 2,774,107 | 2,137,239 |
| Loss from operations | -1,750,515 | -1,967,512 | 644,746 | -1,955,442 |
| Other income and expense, net | 21,011 | 15,879 | 14,683 | 7,394 |
| Interest expense, net | 3,160 | 3,856 | 4,063 | 27,563 |
| Change in fair value of liability classified warrants | -853 | 9,916 | 6,403 | 7,818 |
| Total other income (expense), net | 16,998 | 21,939 | 17,023 | -12,351 |
| Net loss | -1,733,517 | -1,945,573 | 661,769 | -1,967,793 |
| Net loss attributable to noncontrolling interests | -166 | - | - | - |
| Deemed dividend related to warrants down round provision | - | - | - | - |
| Net loss attributable to common stockholders | -1,733,351 | -1,945,573 | 661,769 | -1,967,793 |
| Net income (loss) per share attributable to common stockholders, basic | -0.79 | -1.39 | 0.07 | -0.22 |
| Net income (loss) per share attributable to common stockholders, diluted | -0.79 | -1.39 | 0.07 | -0.22 |
| Weighted average common shares outstanding, basic | 2,202,299 | 1,401,144 | 9,890,390 | 8,817,316 |
| Weighted average common shares outstanding, diluted | 2,202,299 | 1,401,144 | 9,890,390 | 8,817,316 |